News from Cantargia AB A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Cantargia AB

13 Jul, 2018, 14:21 BST Cantargia Approved for Listing on Nasdaq Stockholm First North Premier as Part of the Process Towards Nasdaq Stockholm's Main Market

Cantargia AB ("Cantargia"), as previously announced, intends to list the company on Nasdaq Stockholm main market in 2018. As part of the ongoing...


11 Jul, 2018, 08:17 BST Cantargia Receives Intention to Grant Notification From EPO for Expanded Patent Protection in Treatment of Solid Tumours

Cantargia AB announce that the European Patent Office (EPO) has issued an Intention to grant notification for the company's divisional (second,...


26 Jun, 2018, 14:13 BST Cantargia Announces Pre-clinical Results Showing Positive Effects of CAN04 Combined With Approved Cancer Therapies

Cantargia AB today announces pre-clinical results from a study combining the antibody CAN04 (nidanilimab) and chemotherapy. In in vivo based models...


26 Jun, 2018, 07:43 BST Cantargia Obtains Two New Granted Patents in USA for Antibody-based Cancer Therapy Against IL1RAP

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted two of the company's patent applications. The...


19 Jun, 2018, 14:09 BST Cantargia's Immuno-oncology Antibody CAN04 has Obtained the INN nidanilimab by WHO

Cantargia AB today announces that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) nidanilimab as the...


16 May, 2018, 11:14 BST Cantargia's Immuno-oncology Project CAN04 Shows Promise in Additional Cancer Forms

Cantargia AB today announces that the company has generated novel data showing high levels of interleukin-1 receptor accessory protein (IL1RAP) in...


15 May, 2018, 07:53 BST Cantargia Publishes Interim Report for First Quarter 2018

Cantargia AB's ("Cantargia") interim report for the first quarter of 2018 is now available on the company's web page...


04 May, 2018, 07:39 BST Cantargia's European Patents for Both Leukemia and Solid Tumours Remain Valid After Appeal Period Ends

Cantargia AB ("Cantargia") today announces that the company's European patents covering antibody treatment of leukemia as well as solid tumours...


03 May, 2018, 15:46 BST Cantargia Receives Patent Approval in Canada and Broadens Protection with Respect to Hematological Cancer

Cantargia AB ("Cantargia") today announces that the Canadian patent office ("CIPO") has formally granted the company's application for a patent...


16 Apr, 2018, 14:06 BST Cantargia Presents Anti-metastatic Effect of IL1RAP Blocking Antibody at AACR

Today, Cantargia AB presents novel data using antibody therapy against interleukin 1 receptor accessory protein (IL1RAP) at the American...


15 Mar, 2018, 07:40 GMT Cantargia Presents New Data at AACR on Inhibition of Metastasis by Antibodies Against IL1RAP

Cantargia AB ("Cantargia") today announces that data on the anti-metastatic properties of an antibody against interleukin 1 receptor accessory...


06 Mar, 2018, 14:38 GMT Cantargia: Antibody Against ILRAP Reduce Metastases in Experimental Cancer Model

Cantargia AB ("Cantargia") today announces that antibody blockade of IL1RAP signalling, reduce metastases in an experimental cancer model. The...


27 Feb, 2018, 07:38 GMT Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Leukemia

Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US...


23 Jan, 2018, 13:18 GMT Cantargia's European Patent for Hematological Cancers Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of hematological...


22 Jan, 2018, 10:19 GMT European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Hematological Cancers

In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment...


19 Jan, 2018, 10:43 GMT Cantargia's European Patent for Solid Tumours Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of solid tumours...


09 Jan, 2018, 15:41 GMT European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Solid Tumours

In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment...


05 Jan, 2018, 07:51 GMT Cantargia Receives Patent Approval in China for Antibody Treatment Against IL1RAP in Solid Tumours

Cantargia AB ("Cantargia") announces that the Chinese patent office, the State Intellectual Property Office ("SIPO"), has formally approved the...


04 Jan, 2018, 09:22 GMT Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Solid Tumours

Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the...


10 Nov, 2017, 12:32 GMT Notice of Extraordinary General Meeting in Cantargia AB (publ)

The shareholders of Cantargia AB (publ) are summoned to an extraordinary general meeting on Monday 27 November 2017 at 15.00 CET at Medicon...


09 Nov, 2017, 18:58 GMT Cantargia: Combined Directed Issue and Fully Guaranteed Rights Issue of 232 MSEK for Its Expanded Clinical Program of Immuno-oncology Antibody CAN04

The Board of Directors of Cantargia AB (publ) ("Cantargia" or the "Company") resolved on November 9, 2017 to carry out a directed new share issue...


08 Nov, 2017, 08:50 GMT Cantargia Publishes Interim Report for Third Quarter of 2017

Cantargia AB's ("Cantargia") interim report for the third quarter of 2017 is now available on the company's web page...


13 Oct, 2017, 07:47 BST Cantargia Announces First Patient Treated and Completed a Three Weeks Safety Evaluation Period With Immuno-oncology Antibody CAN04

Cantargia AB ("Cantargia") today announces that the first patient in the CANFOUR clinical trial has received three cycles of treatment with the...


06 Oct, 2017, 10:16 BST Cantargia Obtains Patent Approval in USA for the Antibody CAN04 in Development for Treatment of Cancer

Cantargia AB ("Cantargia") today announces that the United States Patent and Trademark Office ("USPTO") has granted the company's patent...


31 Aug, 2017, 15:26 BST Cantargia Obtains Patent Approval in Europe for the Antibody CAN04 in Development for Treatment of Cancer

Cantargia AB ("Cantargia") today announced that the European Patent Office ("EPO") has granted the company's patent application on...